<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165396</url>
  </required_header>
  <id_info>
    <org_study_id>szxlcyj－chen</org_study_id>
    <nct_id>NCT03165396</nct_id>
  </id_info>
  <brief_title>Appropriate Compatibility of Propofol and Sevoflurane for Orthopaedic Surgery of Patients With MCI</brief_title>
  <acronym>MCI</acronym>
  <official_title>The Appropriate Compatibility of Propofol and Sevoflurane for Orthopaedic Surgery of Patients With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Central Clinical College of Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Central Clinical College of Tianjin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the inclusion and exclusion criteria, elderly patients undergoing elective
      orthopedic surgery were randomly divided into four groups. The different combinations of
      propofol and sevoflurane were used in the four groups: 1 day before surgery, after patients
      become wide-awake, and 3 days, 7 days, and 3 months after surgery, the patient's cognitive
      function was evaluated using a professional cognitive scale and other indicators. Finally,
      statistical analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2016</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of clinically cognitive function decline ：Apolipoprotein J（ApoJ）</measure>
    <time_frame>Change from Baseline Apolipoprotein J at 7 days</time_frame>
    <description>Measurement by ELISA kit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of clinically cognitive function decline ：Soluble CD14（sCD14）</measure>
    <time_frame>Change from Baseline Soluble CD14 at 7 days</time_frame>
    <description>Estimating by ELISA kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini mental Examination(MMSE)</measure>
    <time_frame>preoperative 24 hours ， 7 days post surgery</time_frame>
    <description>A questionnaires is used to assess the cognitive function of patients in clinical.Total range was 0~30，≦27 were considered as cognitive function decline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment（MoCA)</measure>
    <time_frame>preoperative 24 hours ，7 days post surgery</time_frame>
    <description>A questionnaires is used to assess the cognitive function of patients in clinical.Total range was 0~30，≦27 were considered as cognitive function decline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cognitive Impairment, Mild</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.2 μg/ml Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 μg/ml Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol is the most common clinical anesthetics.</description>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>1.2 μg/ml Propofol</arm_group_label>
    <arm_group_label>0.6 μg/ml Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane is the most common clinical anesthetics.</description>
    <arm_group_label>1.2 μg/ml Propofol</arm_group_label>
    <arm_group_label>0.6 μg/ml Propofol</arm_group_label>
    <arm_group_label>Sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective orthopaedic surgery

          -  American Society of Anesthesiologists physical status: II

        Exclusion Criteria:

          -  Neurological diseases that may affect cognitive function (e.g., subdural hematoma)

          -  Hypothyroidism

          -  Alcoholic dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haiyun Wang</last_name>
    <phone>86-13752211206</phone>
    <email>why@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yimeng Chen</last_name>
    <email>chenyimeng5525@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Central Hospital of Tianjin</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyun Wang</last_name>
      <email>why819@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

